Abstract:Introduction: Considering the controversial relationship between blood lipid levels and osteopenia and osteoporosis (OP), we performed this meta-analysis. Materials and methods: Using specific keywords and related words, we searched PubMed, Embase, and Cochrane Library databases. The Newcastle-Ottawa Scale form was used to evaluate the quality of the literature. According to the inclusion and exclusion criteria, we systematically screened the literature to extract relevant information and data. ReVman 5.3 and Stata 13.0 software were used for statistical analysis. Results were expressed as the mean difference (MD) and 95% confidence interval (95% CI). The heterogeneity test was conducted according to I2 and Q tests. Egger's test was used to quantitatively evaluate publication bias. Results: This analysis involved 12 studies (12,395 subjects). The quality of the literature was acceptable. Among subjects who were not taking lipid-lowering drugs, total cholesterol (TC) (MD = 0.11 mmol/L, 95%CI: - 0.03, 0.25; I2 = 21%; P = 0.36), triglycerides (TG) (MD = - 0.01 mmol/L, 95%CI: - 0.09, 0.07; I2 = 6%; P = 0.34), and low-density lipoprotein cholesterol (LDL-C) (MD = 0.10 mmol/L, 95%CI: 0.00, 0.19; I2 = 0%; P = 0.74) in the osteopenia were not significantly increased/decreased. There were no significant differences in LDL-C (MD = 0.02 mmol/L, 95%CI: - 0.09, 0.13; I2 = 0%; P = 0.74) in postmenopausal women in osteopenia. TG (MD = - 0.04 mmol/L, 95%CI: - 0.14,0.07; I2 = 49%; P = 0.07) was unchanged in the osteoporosis (OP) group in subjects without taking lipid-lowering drugs. HDL-C was elevated in OP group (MD = 0.05 mmol/L, 95%CI: 0.03, 0.07; I2 = 31%; P = 0.15) but not in osteopenia group (MD = 0.01 mmol/L, 95%CI: - 0.01, 0.02; I2 = 38%; P = 0.14) in all subjects. Conclusion: HDL-C was elevated in patients with OP.

Lipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review).

Lipid Metabolism Disorders and Bone Dysfunction-Interrelated and Mutually Regulated (Review)

The role of lipid metabolism in osteoporosis: Clinical implication and cellular mechanism

Obesity and lipid metabolism in the development of osteoporosis (Review)

Lipid metabolism within the bone micro-environment is closely associated with bone metabolism in physiological and pathophysiological stages

Crosstalk between Lipid Metabolism and Bone Homeostasis: Exploring Intricate Signaling Relationships

Regulation of Osteoclast Differentiation and Activity by Lipid Metabolism

Therapeutic Potentials And Modulatory Mechanisms Of Fatty Acids In Bone

Mechanisms of Bone Anabolism Regulated by Statins

Bone Health in Patients with Dyslipidemias: An Underestimated Aspect

Hormones and Their Receptors Bridge Fat and Bone Metabolisms

Modulation of Bone and Marrow Niche by Cholesterol.

Review article: non-alcoholic fatty liver disease and osteoporosis--clinical and molecular crosstalk

Hyperlipidemia impacts osteogenesis via lipophagy

Cardiovascular disease and osteoporosis: is there a link between lipids and bone?

Bone Marrow Fat in the Regulation of Bone Metabolism and Its Pathological Role in Osteoporosis

Blood lipid levels in patients with osteopenia and osteoporosis:a systematic review and meta-analysis

The Role of Sphingolipid Metabolism in Bone Remodeling

Bone marrow adiposity during pathologic bone loss: molecular mechanisms underlying the cellular events

Lipidomics analysis of bone marrow in a mouse model of postmenopausal osteoporosis

Mitochondrial dysfunction and therapeutic perspectives in osteoporosis